
    
      A prospective, multicenter, open-label, non-comparative study of safety and efficacy of
      palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe lower respiratory
      tract respiratory syncytial virus infection in 100 Russian children of 2 years of age and
      less in high-risk populations (preterm infants [less than or equal to 35 weeks gestational
      age], infants with bronchopulmonary dysplasia [BPD], and infants with hemodynamically
      significant congenital heart disease [HSCHD]).
    
  